Transdermal Drug Delivery System Comprehensive Study by Type (Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches}, Transdermal Semisolids {Gels, Ointments, Sprays}), Application (Pain Management, Neurological Disorders, Hormone Replacement Therapy, Transdermal Estrogen Therapy, Cardiovascular Diseases, CNS Disorders, Others), End Users (Hospitals & Clinics, Home Care Settings), Category (OTC, Prescription) Players and Region - Global Market Outlook to 2028

Transdermal Drug Delivery System Market by XX Submarkets | Forecast Years 2023-2028  

  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Snapshot:
Transdermal drug delivery system is a controlled drug delivery system in which the drugs can deliver through the skin portal to systemic circulation at a predetermined rate and maintain clinically the effective concentrations over a particular time. The advantages of transdermal drug delivery system are- prolonged therapeutic effect, prolonged duration action, Uniform plasma levels, administration of the complete dose, improved bioavailability, better patient compliance and easy termination of drug therapy. It is widely used for Neurological Disorders Pain Management, Hormone Replacement Therapy, Cardiovascular Diseases, Transdermal Estrogen Therapy, and Smoking Cessation. Transdermal Drug Delivery System is mainly segmented down by Transdermal Patches which includes Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Reservoir, Matrix, Vapor Patch and Transdermal Semisolids that covers Ointments, Gels, Sprays, and others. Moreover, rising Prevalence of Chronic Disorders and Technological Advancements in Drug Delivery Systems anticipated for the growth of Global Transdermal Drug Delivery Systems.

Highlights from Transdermal Drug Delivery System Market Study
AttributesDetails
Study Period2018-2028
Base Year2022
Largest MarketNorth America
UnitValue (USD Million)


The key Players profiled in the report are Hisamitsu Pharmaceutical Co., Inc. (Japan), Novartis AG (Switzerland), Mylan N.V. (United States), Johnson & Johnson (United States), Medherant Limited (United Kingdom), UCB S.A. (Belgium), Endo International, Inc. (Ireland), GlaxoSmithKline PLC (United Kingdom), Boehringer Ingelheim International GmbH (Germany), Acrux Limited (Australia), Luye Pharma Group (China), Lead Chemicals Co., Inc. (Japan), Teva Pharmaceutical Industries Ltd. (Israel), Corium, LLC (United States), Zydus Pharmaceuticals, Inc. (India) and Croda International Plc (United Kingdom). Additionally, other players that are part of this comprehensive study are BRISTOL-MYERS SQUIBB COMPANY (United States), Purdue Pharma L.P. (United States), ECHO THERAPEUTICS, INC. (United States), Lavipharm (Greece) and 3M (United States).

Geographic Breakdown and Segment Analysis
The Global Transdermal Drug Delivery System market presents a comprehensive analysis of the Transdermal Drug Delivery System market by product type (Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches} and Transdermal Semisolids {Gels, Ointments, Sprays}), by end-user/application (Pain Management, Neurological Disorders, Hormone Replacement Therapy, Transdermal Estrogen Therapy, Cardiovascular Diseases, CNS Disorders and Others), and by geography (North America, South America, Europe, Asia-Pacific and MEA) along with country level break-up. This section of our report presents a realistic picture of the Global Transdermal Drug Delivery System industry. Investors and Players can easily understand the inherent opportunities and challenges for their products in geographical region of interest. For instance, while the North America holds majority of market share of the Transdermal Drug Delivery System market

Analyst at AMA have segmented the market study of Global Transdermal Drug Delivery System market by Type, Application and Region. On the basis of Type, Pain Management are dominating the market in the year 2022.

Influencing Trend:
They can be solid, coated, or dissolvable, allowing for precise drug delivery.

Market Growth Drivers:
Increasing Geriatric Population, Rising Prevalence of Chronic Disorders and Technological Advancements in Drug Delivery Systems

Challenges:
Technical Barriers Related To Skin Irritation and Permeability

Restraints:
Side Effects of Systems at the Site of Application

Opportunities:
Collaboration between Pharmaceutical Companies and Drug Delivery Firms and Emerging Nations

Market Developments Activities:
In December 2018 Novartis AG, a multinational company based in Switzerland has acquired Endocyte, Inc., a US-based biopharmaceutical company developing radioligand and CAR-T therapies for cancer treatment. This acquisition will strengthen Novartis AG leadership in nuclear medicine and radiological therapy for treating cancer.
In January 2021, Luey pharma group held press conference to announce the launch Rivastigmine Transderm anal Patch in China the medications is approved treatment of mild to moderate.



In February 2019 Hisamitsu Pharmaceutical Co., Inc., a leader in the manufacturing of transdermal patch has signed commercialization agreement with Kyowa Hakko Kirin Co., Ltd., a Japanese pharmaceutical and biotechnology company for HP-3000 product. The product a systemic transdermal Parkinson’s disease treatment patch developed by Hisamitsu Pharmaceutical’s TDDS (Transdermal Drug Delivery System) technologies for which Kyowa Hakko Kirin will be responsible for commercialization of the product.

Analyst Comment
"The market is mainly broken down by Transdermal Patches which includes Single-layer Drug-in-Adhesive, Multi-layer Drug-in-Adhesive, Reservoir, Matrix, Vapor Patch and Transdermal Semisolids that covers Ointments, Gels, Sprays, and others."

Key Target Audience
Transdermal Drug Delivery System Manufacturers, Raw Materials Suppliers, Government, Research & Development Organizations, Industry Associations, Hospitals and Others

Report Objectives / Segmentation Covered

By Type
  • Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches}
  • Transdermal Semisolids {Gels, Ointments, Sprays}
By Application
  • Pain Management
  • Neurological Disorders
  • Hormone Replacement Therapy
  • Transdermal Estrogen Therapy
  • Cardiovascular Diseases
  • CNS Disorders
  • Others
By End Users
  • Hospitals & Clinics
  • Home Care Settings

By Category
  • OTC
  • Prescription

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Geriatric Population
      • 3.2.2. Rising Prevalence of Chronic Disorders
      • 3.2.3. Technological Advancements in Drug Delivery Systems
    • 3.3. Market Challenges
      • 3.3.1. Technical Barriers Related To Skin Irritation and Permeability
    • 3.4. Market Trends
      • 3.4.1. They can be solid, coated, or dissolvable, allowing for precise drug delivery.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Transdermal Drug Delivery System, by Type, Application, End Users, Category and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Transdermal Drug Delivery System (Value)
      • 5.2.1. Global Transdermal Drug Delivery System by: Type (Value)
        • 5.2.1.1. Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches}
        • 5.2.1.2. Transdermal Semisolids {Gels, Ointments, Sprays}
      • 5.2.2. Global Transdermal Drug Delivery System by: Application (Value)
        • 5.2.2.1. Pain Management
        • 5.2.2.2. Neurological Disorders
        • 5.2.2.3. Hormone Replacement Therapy
        • 5.2.2.4. Transdermal Estrogen Therapy
        • 5.2.2.5. Cardiovascular Diseases
        • 5.2.2.6. CNS Disorders
        • 5.2.2.7. Others
      • 5.2.3. Global Transdermal Drug Delivery System by: End Users (Value)
        • 5.2.3.1. Hospitals & Clinics
        • 5.2.3.2. Home Care Settings
      • 5.2.4. Global Transdermal Drug Delivery System by: Category (Value)
        • 5.2.4.1. OTC
        • 5.2.4.2. Prescription
      • 5.2.5. Global Transdermal Drug Delivery System Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Southeast Asia
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
    • 5.3. Global Transdermal Drug Delivery System (Volume)
      • 5.3.1. Global Transdermal Drug Delivery System by: Type (Volume)
        • 5.3.1.1. Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches}
        • 5.3.1.2. Transdermal Semisolids {Gels, Ointments, Sprays}
      • 5.3.2. Global Transdermal Drug Delivery System by: Application (Volume)
        • 5.3.2.1. Pain Management
        • 5.3.2.2. Neurological Disorders
        • 5.3.2.3. Hormone Replacement Therapy
        • 5.3.2.4. Transdermal Estrogen Therapy
        • 5.3.2.5. Cardiovascular Diseases
        • 5.3.2.6. CNS Disorders
        • 5.3.2.7. Others
      • 5.3.3. Global Transdermal Drug Delivery System by: End Users (Volume)
        • 5.3.3.1. Hospitals & Clinics
        • 5.3.3.2. Home Care Settings
      • 5.3.4. Global Transdermal Drug Delivery System by: Category (Volume)
        • 5.3.4.1. OTC
        • 5.3.4.2. Prescription
      • 5.3.5. Global Transdermal Drug Delivery System Region
        • 5.3.5.1. South America
          • 5.3.5.1.1. Brazil
          • 5.3.5.1.2. Argentina
          • 5.3.5.1.3. Rest of South America
        • 5.3.5.2. Asia Pacific
          • 5.3.5.2.1. China
          • 5.3.5.2.2. Japan
          • 5.3.5.2.3. India
          • 5.3.5.2.4. South Korea
          • 5.3.5.2.5. Southeast Asia
          • 5.3.5.2.6. Australia
          • 5.3.5.2.7. Rest of Asia-Pacific
        • 5.3.5.3. Europe
          • 5.3.5.3.1. Germany
          • 5.3.5.3.2. France
          • 5.3.5.3.3. Italy
          • 5.3.5.3.4. United Kingdom
          • 5.3.5.3.5. Netherlands
          • 5.3.5.3.6. Rest of Europe
        • 5.3.5.4. MEA
          • 5.3.5.4.1. Middle East
          • 5.3.5.4.2. Africa
        • 5.3.5.5. North America
          • 5.3.5.5.1. United States
          • 5.3.5.5.2. Canada
          • 5.3.5.5.3. Mexico
    • 5.4. Global Transdermal Drug Delivery System (Price)
      • 5.4.1. Global Transdermal Drug Delivery System by: Type (Price)
  • 6. Transdermal Drug Delivery System: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Hisamitsu Pharmaceutical Co., Inc. (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Novartis AG (Switzerland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mylan N.V. (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Johnson & Johnson (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Medherant Limited (United Kingdom)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. UCB S.A. (Belgium)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Endo International, Inc. (Ireland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline PLC (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Boehringer Ingelheim International GmbH (Germany)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Acrux Limited (Australia)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Luye Pharma Group (China)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Lead Chemicals Co., Inc. (Japan)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Corium, LLC (United States)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
      • 6.4.15. Zydus Pharmaceuticals, Inc. (India)
        • 6.4.15.1. Business Overview
        • 6.4.15.2. Products/Services Offerings
        • 6.4.15.3. Financial Analysis
        • 6.4.15.4. SWOT Analysis
      • 6.4.16. Croda International Plc (United Kingdom)
        • 6.4.16.1. Business Overview
        • 6.4.16.2. Products/Services Offerings
        • 6.4.16.3. Financial Analysis
        • 6.4.16.4. SWOT Analysis
  • 7. Global Transdermal Drug Delivery System Sale, by Type, Application, End Users, Category and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Transdermal Drug Delivery System (Value)
      • 7.2.1. Global Transdermal Drug Delivery System by: Type (Value)
        • 7.2.1.1. Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches}
        • 7.2.1.2. Transdermal Semisolids {Gels, Ointments, Sprays}
      • 7.2.2. Global Transdermal Drug Delivery System by: Application (Value)
        • 7.2.2.1. Pain Management
        • 7.2.2.2. Neurological Disorders
        • 7.2.2.3. Hormone Replacement Therapy
        • 7.2.2.4. Transdermal Estrogen Therapy
        • 7.2.2.5. Cardiovascular Diseases
        • 7.2.2.6. CNS Disorders
        • 7.2.2.7. Others
      • 7.2.3. Global Transdermal Drug Delivery System by: End Users (Value)
        • 7.2.3.1. Hospitals & Clinics
        • 7.2.3.2. Home Care Settings
      • 7.2.4. Global Transdermal Drug Delivery System by: Category (Value)
        • 7.2.4.1. OTC
        • 7.2.4.2. Prescription
      • 7.2.5. Global Transdermal Drug Delivery System Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Southeast Asia
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
    • 7.3. Global Transdermal Drug Delivery System (Volume)
      • 7.3.1. Global Transdermal Drug Delivery System by: Type (Volume)
        • 7.3.1.1. Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches}
        • 7.3.1.2. Transdermal Semisolids {Gels, Ointments, Sprays}
      • 7.3.2. Global Transdermal Drug Delivery System by: Application (Volume)
        • 7.3.2.1. Pain Management
        • 7.3.2.2. Neurological Disorders
        • 7.3.2.3. Hormone Replacement Therapy
        • 7.3.2.4. Transdermal Estrogen Therapy
        • 7.3.2.5. Cardiovascular Diseases
        • 7.3.2.6. CNS Disorders
        • 7.3.2.7. Others
      • 7.3.3. Global Transdermal Drug Delivery System by: End Users (Volume)
        • 7.3.3.1. Hospitals & Clinics
        • 7.3.3.2. Home Care Settings
      • 7.3.4. Global Transdermal Drug Delivery System by: Category (Volume)
        • 7.3.4.1. OTC
        • 7.3.4.2. Prescription
      • 7.3.5. Global Transdermal Drug Delivery System Region
        • 7.3.5.1. South America
          • 7.3.5.1.1. Brazil
          • 7.3.5.1.2. Argentina
          • 7.3.5.1.3. Rest of South America
        • 7.3.5.2. Asia Pacific
          • 7.3.5.2.1. China
          • 7.3.5.2.2. Japan
          • 7.3.5.2.3. India
          • 7.3.5.2.4. South Korea
          • 7.3.5.2.5. Southeast Asia
          • 7.3.5.2.6. Australia
          • 7.3.5.2.7. Rest of Asia-Pacific
        • 7.3.5.3. Europe
          • 7.3.5.3.1. Germany
          • 7.3.5.3.2. France
          • 7.3.5.3.3. Italy
          • 7.3.5.3.4. United Kingdom
          • 7.3.5.3.5. Netherlands
          • 7.3.5.3.6. Rest of Europe
        • 7.3.5.4. MEA
          • 7.3.5.4.1. Middle East
          • 7.3.5.4.2. Africa
        • 7.3.5.5. North America
          • 7.3.5.5.1. United States
          • 7.3.5.5.2. Canada
          • 7.3.5.5.3. Mexico
    • 7.4. Global Transdermal Drug Delivery System (Price)
      • 7.4.1. Global Transdermal Drug Delivery System by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Transdermal Drug Delivery System: by Type(USD Million)
  • Table 2. Transdermal Drug Delivery System Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches} , by Region USD Million (2017-2022)
  • Table 3. Transdermal Drug Delivery System Transdermal Semisolids {Gels, Ointments, Sprays} , by Region USD Million (2017-2022)
  • Table 4. Transdermal Drug Delivery System: by Application(USD Million)
  • Table 5. Transdermal Drug Delivery System Pain Management , by Region USD Million (2017-2022)
  • Table 6. Transdermal Drug Delivery System Neurological Disorders , by Region USD Million (2017-2022)
  • Table 7. Transdermal Drug Delivery System Hormone Replacement Therapy , by Region USD Million (2017-2022)
  • Table 8. Transdermal Drug Delivery System Transdermal Estrogen Therapy , by Region USD Million (2017-2022)
  • Table 9. Transdermal Drug Delivery System Cardiovascular Diseases , by Region USD Million (2017-2022)
  • Table 10. Transdermal Drug Delivery System CNS Disorders , by Region USD Million (2017-2022)
  • Table 11. Transdermal Drug Delivery System Others , by Region USD Million (2017-2022)
  • Table 12. Transdermal Drug Delivery System: by End Users(USD Million)
  • Table 13. Transdermal Drug Delivery System Hospitals & Clinics , by Region USD Million (2017-2022)
  • Table 14. Transdermal Drug Delivery System Home Care Settings , by Region USD Million (2017-2022)
  • Table 15. Transdermal Drug Delivery System: by Category(USD Million)
  • Table 16. Transdermal Drug Delivery System OTC , by Region USD Million (2017-2022)
  • Table 17. Transdermal Drug Delivery System Prescription , by Region USD Million (2017-2022)
  • Table 18. South America Transdermal Drug Delivery System, by Country USD Million (2017-2022)
  • Table 19. South America Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 20. South America Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 21. South America Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 22. South America Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 23. Brazil Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 24. Brazil Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 25. Brazil Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 26. Brazil Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 27. Argentina Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 28. Argentina Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 29. Argentina Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 30. Argentina Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 31. Rest of South America Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 32. Rest of South America Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 33. Rest of South America Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 34. Rest of South America Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 35. Asia Pacific Transdermal Drug Delivery System, by Country USD Million (2017-2022)
  • Table 36. Asia Pacific Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 37. Asia Pacific Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 38. Asia Pacific Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 39. Asia Pacific Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 40. China Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 41. China Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 42. China Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 43. China Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 44. Japan Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 45. Japan Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 46. Japan Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 47. Japan Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 48. India Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 49. India Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 50. India Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 51. India Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 52. South Korea Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 53. South Korea Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 54. South Korea Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 55. South Korea Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 56. Southeast Asia Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 57. Southeast Asia Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 58. Southeast Asia Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 59. Southeast Asia Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 60. Australia Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 61. Australia Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 62. Australia Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 63. Australia Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 64. Rest of Asia-Pacific Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 68. Europe Transdermal Drug Delivery System, by Country USD Million (2017-2022)
  • Table 69. Europe Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 70. Europe Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 71. Europe Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 72. Europe Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 73. Germany Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 74. Germany Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 75. Germany Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 76. Germany Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 77. France Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 78. France Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 79. France Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 80. France Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 81. Italy Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 82. Italy Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 83. Italy Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 84. Italy Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 85. United Kingdom Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 86. United Kingdom Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 87. United Kingdom Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 88. United Kingdom Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 89. Netherlands Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 90. Netherlands Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 91. Netherlands Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 92. Netherlands Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 93. Rest of Europe Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 94. Rest of Europe Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 95. Rest of Europe Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 96. Rest of Europe Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 97. MEA Transdermal Drug Delivery System, by Country USD Million (2017-2022)
  • Table 98. MEA Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 99. MEA Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 100. MEA Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 101. MEA Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 102. Middle East Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 103. Middle East Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 104. Middle East Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 105. Middle East Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 106. Africa Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 107. Africa Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 108. Africa Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 109. Africa Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 110. North America Transdermal Drug Delivery System, by Country USD Million (2017-2022)
  • Table 111. North America Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 112. North America Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 113. North America Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 114. North America Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 115. United States Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 116. United States Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 117. United States Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 118. United States Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 119. Canada Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 120. Canada Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 121. Canada Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 122. Canada Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 123. Mexico Transdermal Drug Delivery System, by Type USD Million (2017-2022)
  • Table 124. Mexico Transdermal Drug Delivery System, by Application USD Million (2017-2022)
  • Table 125. Mexico Transdermal Drug Delivery System, by End Users USD Million (2017-2022)
  • Table 126. Mexico Transdermal Drug Delivery System, by Category USD Million (2017-2022)
  • Table 127. Transdermal Drug Delivery System Sales: by Type(K Unit)
  • Table 128. Transdermal Drug Delivery System Sales Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches} , by Region K Unit (2017-2022)
  • Table 129. Transdermal Drug Delivery System Sales Transdermal Semisolids {Gels, Ointments, Sprays} , by Region K Unit (2017-2022)
  • Table 130. Transdermal Drug Delivery System Sales: by Application(K Unit)
  • Table 131. Transdermal Drug Delivery System Sales Pain Management , by Region K Unit (2017-2022)
  • Table 132. Transdermal Drug Delivery System Sales Neurological Disorders , by Region K Unit (2017-2022)
  • Table 133. Transdermal Drug Delivery System Sales Hormone Replacement Therapy , by Region K Unit (2017-2022)
  • Table 134. Transdermal Drug Delivery System Sales Transdermal Estrogen Therapy , by Region K Unit (2017-2022)
  • Table 135. Transdermal Drug Delivery System Sales Cardiovascular Diseases , by Region K Unit (2017-2022)
  • Table 136. Transdermal Drug Delivery System Sales CNS Disorders , by Region K Unit (2017-2022)
  • Table 137. Transdermal Drug Delivery System Sales Others , by Region K Unit (2017-2022)
  • Table 138. Transdermal Drug Delivery System Sales: by End Users(K Unit)
  • Table 139. Transdermal Drug Delivery System Sales Hospitals & Clinics , by Region K Unit (2017-2022)
  • Table 140. Transdermal Drug Delivery System Sales Home Care Settings , by Region K Unit (2017-2022)
  • Table 141. Transdermal Drug Delivery System Sales: by Category(K Unit)
  • Table 142. Transdermal Drug Delivery System Sales OTC , by Region K Unit (2017-2022)
  • Table 143. Transdermal Drug Delivery System Sales Prescription , by Region K Unit (2017-2022)
  • Table 144. South America Transdermal Drug Delivery System Sales, by Country K Unit (2017-2022)
  • Table 145. South America Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 146. South America Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 147. South America Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 148. South America Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 149. Brazil Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 150. Brazil Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 151. Brazil Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 152. Brazil Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 153. Argentina Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 154. Argentina Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 155. Argentina Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 156. Argentina Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 157. Rest of South America Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 158. Rest of South America Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 159. Rest of South America Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 160. Rest of South America Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 161. Asia Pacific Transdermal Drug Delivery System Sales, by Country K Unit (2017-2022)
  • Table 162. Asia Pacific Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 163. Asia Pacific Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 164. Asia Pacific Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 165. Asia Pacific Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 166. China Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 167. China Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 168. China Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 169. China Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 170. Japan Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 171. Japan Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 172. Japan Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 173. Japan Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 174. India Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 175. India Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 176. India Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 177. India Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 178. South Korea Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 179. South Korea Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 180. South Korea Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 181. South Korea Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 182. Southeast Asia Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 183. Southeast Asia Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 184. Southeast Asia Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 185. Southeast Asia Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 186. Australia Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 187. Australia Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 188. Australia Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 189. Australia Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 190. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 191. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 192. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 193. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 194. Europe Transdermal Drug Delivery System Sales, by Country K Unit (2017-2022)
  • Table 195. Europe Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 196. Europe Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 197. Europe Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 198. Europe Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 199. Germany Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 200. Germany Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 201. Germany Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 202. Germany Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 203. France Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 204. France Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 205. France Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 206. France Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 207. Italy Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 208. Italy Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 209. Italy Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 210. Italy Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 211. United Kingdom Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 212. United Kingdom Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 213. United Kingdom Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 214. United Kingdom Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 215. Netherlands Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 216. Netherlands Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 217. Netherlands Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 218. Netherlands Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 219. Rest of Europe Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 220. Rest of Europe Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 221. Rest of Europe Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 222. Rest of Europe Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 223. MEA Transdermal Drug Delivery System Sales, by Country K Unit (2017-2022)
  • Table 224. MEA Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 225. MEA Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 226. MEA Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 227. MEA Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 228. Middle East Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 229. Middle East Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 230. Middle East Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 231. Middle East Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 232. Africa Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 233. Africa Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 234. Africa Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 235. Africa Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 236. North America Transdermal Drug Delivery System Sales, by Country K Unit (2017-2022)
  • Table 237. North America Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 238. North America Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 239. North America Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 240. North America Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 241. United States Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 242. United States Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 243. United States Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 244. United States Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 245. Canada Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 246. Canada Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 247. Canada Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 248. Canada Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 249. Mexico Transdermal Drug Delivery System Sales, by Type K Unit (2017-2022)
  • Table 250. Mexico Transdermal Drug Delivery System Sales, by Application K Unit (2017-2022)
  • Table 251. Mexico Transdermal Drug Delivery System Sales, by End Users K Unit (2017-2022)
  • Table 252. Mexico Transdermal Drug Delivery System Sales, by Category K Unit (2017-2022)
  • Table 253. Transdermal Drug Delivery System: by Type(USD/Units)
  • Table 254. Company Basic Information, Sales Area and Its Competitors
  • Table 255. Company Basic Information, Sales Area and Its Competitors
  • Table 256. Company Basic Information, Sales Area and Its Competitors
  • Table 257. Company Basic Information, Sales Area and Its Competitors
  • Table 258. Company Basic Information, Sales Area and Its Competitors
  • Table 259. Company Basic Information, Sales Area and Its Competitors
  • Table 260. Company Basic Information, Sales Area and Its Competitors
  • Table 261. Company Basic Information, Sales Area and Its Competitors
  • Table 262. Company Basic Information, Sales Area and Its Competitors
  • Table 263. Company Basic Information, Sales Area and Its Competitors
  • Table 264. Company Basic Information, Sales Area and Its Competitors
  • Table 265. Company Basic Information, Sales Area and Its Competitors
  • Table 266. Company Basic Information, Sales Area and Its Competitors
  • Table 267. Company Basic Information, Sales Area and Its Competitors
  • Table 268. Company Basic Information, Sales Area and Its Competitors
  • Table 269. Company Basic Information, Sales Area and Its Competitors
  • Table 270. Transdermal Drug Delivery System: by Type(USD Million)
  • Table 271. Transdermal Drug Delivery System Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches} , by Region USD Million (2023-2028)
  • Table 272. Transdermal Drug Delivery System Transdermal Semisolids {Gels, Ointments, Sprays} , by Region USD Million (2023-2028)
  • Table 273. Transdermal Drug Delivery System: by Application(USD Million)
  • Table 274. Transdermal Drug Delivery System Pain Management , by Region USD Million (2023-2028)
  • Table 275. Transdermal Drug Delivery System Neurological Disorders , by Region USD Million (2023-2028)
  • Table 276. Transdermal Drug Delivery System Hormone Replacement Therapy , by Region USD Million (2023-2028)
  • Table 277. Transdermal Drug Delivery System Transdermal Estrogen Therapy , by Region USD Million (2023-2028)
  • Table 278. Transdermal Drug Delivery System Cardiovascular Diseases , by Region USD Million (2023-2028)
  • Table 279. Transdermal Drug Delivery System CNS Disorders , by Region USD Million (2023-2028)
  • Table 280. Transdermal Drug Delivery System Others , by Region USD Million (2023-2028)
  • Table 281. Transdermal Drug Delivery System: by End Users(USD Million)
  • Table 282. Transdermal Drug Delivery System Hospitals & Clinics , by Region USD Million (2023-2028)
  • Table 283. Transdermal Drug Delivery System Home Care Settings , by Region USD Million (2023-2028)
  • Table 284. Transdermal Drug Delivery System: by Category(USD Million)
  • Table 285. Transdermal Drug Delivery System OTC , by Region USD Million (2023-2028)
  • Table 286. Transdermal Drug Delivery System Prescription , by Region USD Million (2023-2028)
  • Table 287. South America Transdermal Drug Delivery System, by Country USD Million (2023-2028)
  • Table 288. South America Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 289. South America Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 290. South America Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 291. South America Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 292. Brazil Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 293. Brazil Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 294. Brazil Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 295. Brazil Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 296. Argentina Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 297. Argentina Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 298. Argentina Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 299. Argentina Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 300. Rest of South America Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 301. Rest of South America Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 302. Rest of South America Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 303. Rest of South America Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 304. Asia Pacific Transdermal Drug Delivery System, by Country USD Million (2023-2028)
  • Table 305. Asia Pacific Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 306. Asia Pacific Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 307. Asia Pacific Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 308. Asia Pacific Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 309. China Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 310. China Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 311. China Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 312. China Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 313. Japan Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 314. Japan Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 315. Japan Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 316. Japan Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 317. India Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 318. India Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 319. India Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 320. India Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 321. South Korea Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 322. South Korea Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 323. South Korea Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 324. South Korea Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 325. Southeast Asia Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 326. Southeast Asia Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 327. Southeast Asia Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 328. Southeast Asia Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 329. Australia Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 330. Australia Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 331. Australia Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 332. Australia Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 333. Rest of Asia-Pacific Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 334. Rest of Asia-Pacific Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 335. Rest of Asia-Pacific Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 336. Rest of Asia-Pacific Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 337. Europe Transdermal Drug Delivery System, by Country USD Million (2023-2028)
  • Table 338. Europe Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 339. Europe Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 340. Europe Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 341. Europe Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 342. Germany Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 343. Germany Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 344. Germany Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 345. Germany Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 346. France Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 347. France Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 348. France Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 349. France Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 350. Italy Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 351. Italy Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 352. Italy Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 353. Italy Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 354. United Kingdom Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 355. United Kingdom Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 356. United Kingdom Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 357. United Kingdom Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 358. Netherlands Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 359. Netherlands Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 360. Netherlands Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 361. Netherlands Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 362. Rest of Europe Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 363. Rest of Europe Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 364. Rest of Europe Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 365. Rest of Europe Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 366. MEA Transdermal Drug Delivery System, by Country USD Million (2023-2028)
  • Table 367. MEA Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 368. MEA Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 369. MEA Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 370. MEA Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 371. Middle East Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 372. Middle East Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 373. Middle East Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 374. Middle East Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 375. Africa Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 376. Africa Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 377. Africa Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 378. Africa Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 379. North America Transdermal Drug Delivery System, by Country USD Million (2023-2028)
  • Table 380. North America Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 381. North America Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 382. North America Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 383. North America Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 384. United States Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 385. United States Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 386. United States Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 387. United States Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 388. Canada Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 389. Canada Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 390. Canada Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 391. Canada Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 392. Mexico Transdermal Drug Delivery System, by Type USD Million (2023-2028)
  • Table 393. Mexico Transdermal Drug Delivery System, by Application USD Million (2023-2028)
  • Table 394. Mexico Transdermal Drug Delivery System, by End Users USD Million (2023-2028)
  • Table 395. Mexico Transdermal Drug Delivery System, by Category USD Million (2023-2028)
  • Table 396. Transdermal Drug Delivery System Sales: by Type(K Unit)
  • Table 397. Transdermal Drug Delivery System Sales Transdermal Patches {Drug-In-Adhesive Patches, Matrix Patches, Reservoir Membrane Patches, Microneedle Patches} , by Region K Unit (2023-2028)
  • Table 398. Transdermal Drug Delivery System Sales Transdermal Semisolids {Gels, Ointments, Sprays} , by Region K Unit (2023-2028)
  • Table 399. Transdermal Drug Delivery System Sales: by Application(K Unit)
  • Table 400. Transdermal Drug Delivery System Sales Pain Management , by Region K Unit (2023-2028)
  • Table 401. Transdermal Drug Delivery System Sales Neurological Disorders , by Region K Unit (2023-2028)
  • Table 402. Transdermal Drug Delivery System Sales Hormone Replacement Therapy , by Region K Unit (2023-2028)
  • Table 403. Transdermal Drug Delivery System Sales Transdermal Estrogen Therapy , by Region K Unit (2023-2028)
  • Table 404. Transdermal Drug Delivery System Sales Cardiovascular Diseases , by Region K Unit (2023-2028)
  • Table 405. Transdermal Drug Delivery System Sales CNS Disorders , by Region K Unit (2023-2028)
  • Table 406. Transdermal Drug Delivery System Sales Others , by Region K Unit (2023-2028)
  • Table 407. Transdermal Drug Delivery System Sales: by End Users(K Unit)
  • Table 408. Transdermal Drug Delivery System Sales Hospitals & Clinics , by Region K Unit (2023-2028)
  • Table 409. Transdermal Drug Delivery System Sales Home Care Settings , by Region K Unit (2023-2028)
  • Table 410. Transdermal Drug Delivery System Sales: by Category(K Unit)
  • Table 411. Transdermal Drug Delivery System Sales OTC , by Region K Unit (2023-2028)
  • Table 412. Transdermal Drug Delivery System Sales Prescription , by Region K Unit (2023-2028)
  • Table 413. South America Transdermal Drug Delivery System Sales, by Country K Unit (2023-2028)
  • Table 414. South America Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 415. South America Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 416. South America Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 417. South America Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 418. Brazil Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 419. Brazil Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 420. Brazil Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 421. Brazil Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 422. Argentina Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 423. Argentina Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 424. Argentina Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 425. Argentina Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 426. Rest of South America Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 427. Rest of South America Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 428. Rest of South America Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 429. Rest of South America Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 430. Asia Pacific Transdermal Drug Delivery System Sales, by Country K Unit (2023-2028)
  • Table 431. Asia Pacific Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 432. Asia Pacific Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 433. Asia Pacific Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 434. Asia Pacific Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 435. China Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 436. China Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 437. China Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 438. China Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 439. Japan Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 440. Japan Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 441. Japan Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 442. Japan Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 443. India Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 444. India Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 445. India Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 446. India Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 447. South Korea Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 448. South Korea Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 449. South Korea Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 450. South Korea Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 451. Southeast Asia Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 452. Southeast Asia Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 453. Southeast Asia Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 454. Southeast Asia Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 455. Australia Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 456. Australia Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 457. Australia Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 458. Australia Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 459. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 460. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 461. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 462. Rest of Asia-Pacific Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 463. Europe Transdermal Drug Delivery System Sales, by Country K Unit (2023-2028)
  • Table 464. Europe Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 465. Europe Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 466. Europe Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 467. Europe Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 468. Germany Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 469. Germany Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 470. Germany Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 471. Germany Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 472. France Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 473. France Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 474. France Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 475. France Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 476. Italy Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 477. Italy Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 478. Italy Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 479. Italy Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 480. United Kingdom Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 481. United Kingdom Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 482. United Kingdom Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 483. United Kingdom Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 484. Netherlands Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 485. Netherlands Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 486. Netherlands Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 487. Netherlands Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 488. Rest of Europe Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 489. Rest of Europe Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 490. Rest of Europe Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 491. Rest of Europe Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 492. MEA Transdermal Drug Delivery System Sales, by Country K Unit (2023-2028)
  • Table 493. MEA Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 494. MEA Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 495. MEA Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 496. MEA Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 497. Middle East Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 498. Middle East Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 499. Middle East Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 500. Middle East Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 501. Africa Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 502. Africa Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 503. Africa Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 504. Africa Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 505. North America Transdermal Drug Delivery System Sales, by Country K Unit (2023-2028)
  • Table 506. North America Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 507. North America Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 508. North America Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 509. North America Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 510. United States Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 511. United States Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 512. United States Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 513. United States Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 514. Canada Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 515. Canada Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 516. Canada Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 517. Canada Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 518. Mexico Transdermal Drug Delivery System Sales, by Type K Unit (2023-2028)
  • Table 519. Mexico Transdermal Drug Delivery System Sales, by Application K Unit (2023-2028)
  • Table 520. Mexico Transdermal Drug Delivery System Sales, by End Users K Unit (2023-2028)
  • Table 521. Mexico Transdermal Drug Delivery System Sales, by Category K Unit (2023-2028)
  • Table 522. Transdermal Drug Delivery System: by Type(USD/Units)
  • Table 523. Research Programs/Design for This Report
  • Table 524. Key Data Information from Secondary Sources
  • Table 525. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Transdermal Drug Delivery System: by Type USD Million (2017-2022)
  • Figure 5. Global Transdermal Drug Delivery System: by Application USD Million (2017-2022)
  • Figure 6. Global Transdermal Drug Delivery System: by End Users USD Million (2017-2022)
  • Figure 7. Global Transdermal Drug Delivery System: by Category USD Million (2017-2022)
  • Figure 8. South America Transdermal Drug Delivery System Share (%), by Country
  • Figure 9. Asia Pacific Transdermal Drug Delivery System Share (%), by Country
  • Figure 10. Europe Transdermal Drug Delivery System Share (%), by Country
  • Figure 11. MEA Transdermal Drug Delivery System Share (%), by Country
  • Figure 12. North America Transdermal Drug Delivery System Share (%), by Country
  • Figure 13. Global Transdermal Drug Delivery System: by Type K Unit (2017-2022)
  • Figure 14. Global Transdermal Drug Delivery System: by Application K Unit (2017-2022)
  • Figure 15. Global Transdermal Drug Delivery System: by End Users K Unit (2017-2022)
  • Figure 16. Global Transdermal Drug Delivery System: by Category K Unit (2017-2022)
  • Figure 17. South America Transdermal Drug Delivery System Share (%), by Country
  • Figure 18. Asia Pacific Transdermal Drug Delivery System Share (%), by Country
  • Figure 19. Europe Transdermal Drug Delivery System Share (%), by Country
  • Figure 20. MEA Transdermal Drug Delivery System Share (%), by Country
  • Figure 21. North America Transdermal Drug Delivery System Share (%), by Country
  • Figure 22. Global Transdermal Drug Delivery System: by Type USD/Units (2017-2022)
  • Figure 23. Global Transdermal Drug Delivery System share by Players 2022 (%)
  • Figure 24. Global Transdermal Drug Delivery System share by Players (Top 3) 2022(%)
  • Figure 25. Global Transdermal Drug Delivery System share by Players (Top 5) 2022(%)
  • Figure 26. BCG Matrix for key Companies
  • Figure 27. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Hisamitsu Pharmaceutical Co., Inc. (Japan) Revenue: by Geography 2022
  • Figure 29. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis AG (Switzerland) Revenue: by Geography 2022
  • Figure 31. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 32. Mylan N.V. (United States) Revenue: by Geography 2022
  • Figure 33. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 34. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 35. Medherant Limited (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 36. Medherant Limited (United Kingdom) Revenue: by Geography 2022
  • Figure 37. UCB S.A. (Belgium) Revenue, Net Income and Gross profit
  • Figure 38. UCB S.A. (Belgium) Revenue: by Geography 2022
  • Figure 39. Endo International, Inc. (Ireland) Revenue, Net Income and Gross profit
  • Figure 40. Endo International, Inc. (Ireland) Revenue: by Geography 2022
  • Figure 41. GlaxoSmithKline PLC (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 42. GlaxoSmithKline PLC (United Kingdom) Revenue: by Geography 2022
  • Figure 43. Boehringer Ingelheim International GmbH (Germany) Revenue, Net Income and Gross profit
  • Figure 44. Boehringer Ingelheim International GmbH (Germany) Revenue: by Geography 2022
  • Figure 45. Acrux Limited (Australia) Revenue, Net Income and Gross profit
  • Figure 46. Acrux Limited (Australia) Revenue: by Geography 2022
  • Figure 47. Luye Pharma Group (China) Revenue, Net Income and Gross profit
  • Figure 48. Luye Pharma Group (China) Revenue: by Geography 2022
  • Figure 49. Lead Chemicals Co., Inc. (Japan) Revenue, Net Income and Gross profit
  • Figure 50. Lead Chemicals Co., Inc. (Japan) Revenue: by Geography 2022
  • Figure 51. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 52. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2022
  • Figure 53. Corium, LLC (United States) Revenue, Net Income and Gross profit
  • Figure 54. Corium, LLC (United States) Revenue: by Geography 2022
  • Figure 55. Zydus Pharmaceuticals, Inc. (India) Revenue, Net Income and Gross profit
  • Figure 56. Zydus Pharmaceuticals, Inc. (India) Revenue: by Geography 2022
  • Figure 57. Croda International Plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 58. Croda International Plc (United Kingdom) Revenue: by Geography 2022
  • Figure 59. Global Transdermal Drug Delivery System: by Type USD Million (2023-2028)
  • Figure 60. Global Transdermal Drug Delivery System: by Application USD Million (2023-2028)
  • Figure 61. Global Transdermal Drug Delivery System: by End Users USD Million (2023-2028)
  • Figure 62. Global Transdermal Drug Delivery System: by Category USD Million (2023-2028)
  • Figure 63. South America Transdermal Drug Delivery System Share (%), by Country
  • Figure 64. Asia Pacific Transdermal Drug Delivery System Share (%), by Country
  • Figure 65. Europe Transdermal Drug Delivery System Share (%), by Country
  • Figure 66. MEA Transdermal Drug Delivery System Share (%), by Country
  • Figure 67. North America Transdermal Drug Delivery System Share (%), by Country
  • Figure 68. Global Transdermal Drug Delivery System: by Type K Unit (2023-2028)
  • Figure 69. Global Transdermal Drug Delivery System: by Application K Unit (2023-2028)
  • Figure 70. Global Transdermal Drug Delivery System: by End Users K Unit (2023-2028)
  • Figure 71. Global Transdermal Drug Delivery System: by Category K Unit (2023-2028)
  • Figure 72. South America Transdermal Drug Delivery System Share (%), by Country
  • Figure 73. Asia Pacific Transdermal Drug Delivery System Share (%), by Country
  • Figure 74. Europe Transdermal Drug Delivery System Share (%), by Country
  • Figure 75. MEA Transdermal Drug Delivery System Share (%), by Country
  • Figure 76. North America Transdermal Drug Delivery System Share (%), by Country
  • Figure 77. Global Transdermal Drug Delivery System: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Hisamitsu Pharmaceutical Co., Inc. (Japan)
  • Novartis AG (Switzerland)
  • Mylan N.V. (United States)
  • Johnson & Johnson (United States)
  • Medherant Limited (United Kingdom)
  • UCB S.A. (Belgium)
  • Endo International, Inc. (Ireland)
  • GlaxoSmithKline PLC (United Kingdom)
  • Boehringer Ingelheim International GmbH (Germany)
  • Acrux Limited (Australia)
  • Luye Pharma Group (China)
  • Lead Chemicals Co., Inc. (Japan)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Corium, LLC (United States)
  • Zydus Pharmaceuticals, Inc. (India)
  • Croda International Plc (United Kingdom)
Additional players considered in the study are as follows:
BRISTOL-MYERS SQUIBB COMPANY (United States) , Purdue Pharma L.P. (United States) , ECHO THERAPEUTICS, INC. (United States) , Lavipharm (Greece) , 3M (United States)
Select User Access Type

Key Highlights of Report


Dec 2023 238 Pages 51 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Due to pricing constraints we only profile limited players in the study that includes a mix list of leaders and emerging players, however for evaluation of market size the coverage includes 100+ players.
Yes, the study does represent market size by key business segment, application/end users and major geographies forecasted till 2028
The Study can be customized to meet your requirements. Please connect with our representative, in case you wish to add or remove certain country or profiled players.
  • Technical Barriers Related To Skin Irritation and Permeability

Know More About Global Transdermal Drug Delivery System Report?